Cardiovasc Drugs Ther
-
Publication Venue For
- Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.. 34:515-523. 2020
- Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.. 33:615-623. 2019
- BSCR Autumn Meeting Abstracts.. 261-274. 2019
- The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study.. 32:435-442. 2018
- Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.. 31:545-549. 2017
- Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.. 31:419-431. 2017
- Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.. 31:445-458. 2017
- Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.. 31:295-301. 2017
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.. 30:473-483. 2016
- Novel oral anticoagulants after acute coronary syndromes.. 26:265-271. 2012
- Stroke prevention in atrial fibrillation.. 25:561-570. 2011
- Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes.. 25:215-222. 2011
- An introduction to small non-coding RNAs: miRNA and snoRNA.. 25:151-159. 2011